Published online before print November 21, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,,1
,¶,2
* Graduate Institute of Life Sciences, Departments of
Microbiology and Immunology,
Medicine, and
|| Surgery, National Defense Medical Center, Taipei, Taiwan;
Department of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan;
Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan;
¶ Department of Chemical Engineering, National Taipei University of Technology, Taiwan; and
** Division of General Surgery, Armed Force Taoyuan General Hospital, Taiwan
1 Correspondence: Department of Microbiology and Immunology, National Defense Medical Center, 161, Section 6, MinChuan East Road, Neihu, Taipei, Taiwan 114. E-mail: sytwu{at}ndmctsgh.edu.tw
To investigate the regulatory effects of decoy receptor 3 (DcR3) on the differentiation and function of dendritic cells (DCs), bone marrow-derived DCs (BM-DCs) from nonobese diabetic (NOD) mice were cultured with recombinant DcR3.Fc protein. Their differentiating phenotypes and T cell-stimulating functions were then evaluated. Expression of CD11c, CD40, CD54, and major histocompatibility complex I-Ag7 was reduced in cells cultured with additional DcR3.Fc, compared with DCs incubated with granulocyte macrophage-colony stimulating factor and interleukin (IL)-4, indicating that DcR3 interferes with the differentiation and maturation of BM-DCs. One of the most striking effects of DcR3.Fc on the differentiation of DCs was the up-regulation of CD86 and down-regulation of CD80, suggesting a modulatory potential to skew the T cell response toward the T helper cell type 2 (Th2) phenotype. Consistent with this, the proliferation of CD4+ T cells cocultured with DcR3.Fc-treated DCs was significantly reduced compared with that of T cells stimulated by normal DCs. Moreover, the secretion of interferon-
from T cells cocultured with DcR3.Fc-treated DCs was profoundly suppressed, indicating that DcR3 exerts a Th1-suppressing effect on differentiating DCs. Furthermore, adoptive transfer experiments revealed that NOD/severe combined immunodeficiency mice received DcR3.Fc-treated DCs, and subsequently, autoreactive T cells showed delayed onset of diabetes and a decrease in diabetic severity compared with mice that received normal DCs and T cells, suggesting a future therapeutic potential in autoimmune diabetes. Data from two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight analysis show an up-regulation of some proteins—such as mitogen-activated protein kinase p38 ß, cyclin-dependent kinase 6, and signal-induced proliferation-associated gene 1—and a down-regulation of the IL-17 precursor; tumor necrosis factor-related apoptosis-inducing ligand family member-associated nuclear factor-
B activator-binding kinase 1; and Golgi S-nitroso-N-acetylpenicillamine in cells treated with DcR3, further demonstrating its effect on DC differentiation and function.
Key Words: CD80 • CD86 • IFN- • proteomics
This article has been cited by other articles:
 |
|
 |
|
  T.-L. Hsu, Y.-Y. Wu, Y.-C. Chang, C.-Y. Yang, M.-Z. Lai, W. B. Su, and S.-L. Hsieh Attenuation of Th1 Response in Decoy Receptor 3 Transgenic Mice J. Immunol., October 15, 2005; 175(8): 5135 - 5145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Yang, S.-L. Hsieh, F.-M. Ho, and W.-W. Lin Decoy Receptor 3 Increases Monocyte Adhesion to Endothelial Cells via NF-{kappa}B-Dependent Up-Regulation of Intercellular Adhesion Molecule-1, VCAM-1, and IL-8 Expression J. Immunol., February 1, 2005; 174(3): 1647 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-H. Sung, J.-H. Juang, Y.-C. Lin, C.-H. Kuo, J.-T. Hung, A. Chen, D.-M. Chang, S.-Y. Chang, S.-L. Hsieh, and H.-K. Sytwu Transgenic Expression of Decoy Receptor 3 Protects Islets from Spontaneous and Chemical-induced Autoimmune Destruction in Nonobese Diabetic Mice J. Exp. Med., April 19, 2004; 199(8): 1143 - 1151. [Abstract] [Full Text] [PDF]
|
|
